telmisartan 40 zydus tablets
zydus healthcare (pty) ltd - tablets - not indicated - each tablet contains telmisartan 40,0 mg
telmisartan 80 zydus tablets
zydus healthcare (pty) ltd - tablets - not indicated - each tablet contains telmisartan 80,0 mg
sucralfate tablet
zydus lifesciences limited - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate tablets are indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.
sitagliptin 25 zydus #n/a
zydus healthcare (pty) ltd - #n/a - not indicated - none
sitagliptin 50 zydus #n/a
zydus healthcare (pty) ltd - #n/a - not indicated - none
sitagliptin 100 zydus #n/a
zydus healthcare (pty) ltd - #n/a - not indicated - none
sitagliptin/metformin 50/500 zydus #n/a
zydus healthcare (pty) ltd - #n/a - not indicated - none
sitagliptin/metformin 50/1000 zydus #n/a
zydus healthcare (pty) ltd - #n/a - not indicated - none
erlotinib zydus 25 tablet
zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains erlotinib hydrochloride equivalent to erlotinib 25,0 mg
erlotinib zydus 100 tablet
zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains erlotinib hydrochloride equivalent to erlotinib 100,0 mg